Author

M. Sakharkar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 5 Organism:human· 4 Assay:proteomics· 4 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Organism:mouse· 1

Frequent Co-Authors

L. M. Walker· 5 shared A. S. Herbert· 3 shared A. Z. Wec· 3 shared C. M. O'Brien· 3 shared D. Haslwanter· 3 shared D. Wrapp· 3 shared J. M. Dye· 3 shared J. S. McLellan· 3 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

L. M. Walker

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Characterization of SARS-CoV-2 Convalescent Patients' Serological Repertoire Reveals High Prevalence of Iso-RBD Antibodies

N. C. Curtis, S. Shin, A. P. Hederman, R. I. Connor, W. F. Wieland-Alter, S. Ionov, J. Boylston, J. Rose, M. Sakharkar, D. B. Dorman, J. A. Dessaint, L. L. Gwilt, A. R. Crowley, J. Feldman, B. M. Hauser, , J. Lee

This study characterizes the serological repertoire of SARS-CoV-2 convalescent patients, revealing a high prevalence of iso-RBD antibodies that do not recognize prefusion-stabilized S, and shows that vaccination with prefusion-stabilized S reduces their prevalence.

bioRxiv · Sep 8, 2023 · PreprintImmunology

Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection

C. I. Kaku, A. J. Bergeron, C. Ahlm, J. Normark, M. Sakharkar, M. N. Forsell, L. M. Walker

BA.1 breakthrough infection activates pre-existing memory B cells with broad activity against SARS-CoV-2 variants.

bioRxiv · Apr 1, 2022 · PreprintImmunology

Genotype-specific Features Reduce the Susceptibility of South American Yellow Fever Virus Strains to Vaccine-Induced Antibodies

D. Haslwanter, G. Lasso, A. Z. Wec, N. D. Furtado, L. M. S. Raphael, Y. Sun, S. Stransky, N. Pedreno-Lopez, A. Tse, C. A. Correia, Z. A. Bornholdt, M. Sakharkar, V. I. Avelino-Silva, C. L. Moyer, D. I. Watkins, , K. Chandran

This study shows that South American yellow fever virus strains are less susceptible to vaccine-induced antibodies due to genetic changes in the glycoprotein E.

bioRxiv · Aug 22, 2021Microbiology

A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants

D. Haslwanter, M. E. Dieterle, A. Z. Wec, C. M. O'Brien, M. Sakharkar, C. Florez, K. Tong, C. G. Rappazzo, G. Lasso, O. Vergnolle, A. S. Wirchnianski, R. H. Bortz, E. Laudermilch, J. M. Fels, A. Mengotto, , R. K. Jangra

This paper identifies NTD-targeting neutralizing antibodies and shows that combining RBD and NTD antibodies reduces the emergence of neutralization-escape mutants.

bioRxiv · Jun 10, 2021Microbiology

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

C. G. Rappazzo, L. V. Tse, C. I. Kaku, D. Wrapp, M. Sakharkar, D. Huang, L. M. Deveau, T. J. Yockachonis, A. S. Herbert, M. B. Battles, C. M. O'Brien, M. E. Brown, J. C. Geoghegan, J. Belk, L. Peng, , L. M. Walker

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

bioRxiv · Nov 17, 2020 · PreprintImmunology

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein

A. Z. Wec, D. Wrapp, A. S. Herbert, D. P. Maurer, D. Haslwanter, M. Sakharkar, R. K. Jangra, M. E. Dieterle, A. Lilov, D. Huang, L. V. Tse, N. V. Johnson, C.-L. Hsieh, N. Wang, J. H. Nett, , L. M. Walker

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

bioRxiv · May 15, 2020 · PreprintImmunology